14:47 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

GenSight's GS010 misses in Phase III for neuropathy

GenSight Biologics S.A. (Euronext:SIGHT) reported that GS010 (rAAV2/2-ND4) missed the primary endpoint of improving visual acuity in the Phase III REVERSE trial to treat Leber's hereditary optic neuropathy (LHON). On the 37-patient trial's primary endpoint, both...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other molecule...
21:35 , Apr 4, 2018 |  BC Extra  |  Clinical News

GenSight falls after Phase III neuropathy miss

GenSight Biologics S.A. (Euronext:SIGHT) fell €2.71 (48%) to €2.97 on Wednesday after reporting that GS010 (rAAV2/2-ND4) missed the primary endpoint of improving visual acuity in the Phase III REVERSE trial to treat Leber's hereditary optic...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Minipig studies suggest inhibiting MT-ND1 or oxidative damage could help treat post-traumatic osteoarthritis. In a minipig model of ankle intra-articular fracture treated with surgical fixation, an oral MT-ND1 inhibitor tool compound or a hydrogel-suspended...
02:05 , Feb 22, 2017 |  BC Week In Review  |  Clinical News

GS010: Completed Ph III REVERSE enrollment

GenSight completed enrollment of 36 patients in the double-blind, sham-controlled, international Phase III REVERSE trial evaluating a single intravitreal injection of GS010. The trial enrolled patients with an onset of vision loss of 7-12 months...
14:08 , Nov 30, 2016 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers; tissue markers A panel of plasma and urine markers could help predict disease progression and monitor treatment responses in Huntington’s disease (HD). In a mouse model of HD, low plasma levels of NADH...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

RAAV2/2_ND4: Phase III amended

GenSight amended the ongoing, double-blind, sham-controlled, international Phase III RESCUE trial evaluating single intravitreal injections of GS010 to include patients ages 15-18. The trial now plans to enroll about 36 patients ages >=15 with an...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

RAAV2/2_ND4: Phase III amended

GenSight amended the ongoing, double-blind, sham-controlled, international Phase III REVERSE trial evaluating single intravitreal injections of GS010 to include patients ages 15-18. The trial now plans to enroll about 36 patients ages >=15 with an...
00:30 , Jul 14, 2016 |  BC Extra  |  Financial News

GenSight raises EUR 40M in Euronext IPO

Gene therapy company GenSight Biologics S.A. (Euronext:SIGHT) raised EUR 40 million ($44.1 million) through the sale of 5 million shares at EUR 8 in an IPO on Euronext Paris. The offering valued the company at...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

RAAV2/2_ND4: Phase III started

GenSight began the double-blind, sham-controlled, international Phase III RESCUE trial to evaluate single intravitreal injections of GS010 in about 36 patients with an onset of vision loss of <=6 months. Patients will receive GS010 in...